Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of “Hold” from Analysts

Fulgent Genetics, Inc. (NASDAQ:FLGT) has been assigned an average rating of “Hold” from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $32.00.

A number of research firms recently weighed in on FLGT. Wall Street Zen lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulgent Genetics in a report on Thursday, January 22nd. Finally, Zacks Research lowered Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th.

Fulgent Genetics Trading Down 3.3%

FLGT stock opened at $14.80 on Thursday. The firm has a market capitalization of $440.30 million, a PE ratio of -7.55 and a beta of 0.89. Fulgent Genetics has a 1-year low of $13.46 and a 1-year high of $31.04. The business’s 50 day simple moving average is $16.47 and its 200 day simple moving average is $22.87.

Fulgent Genetics (NASDAQ:FLGT) last posted its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.14. The business had revenue of $83.34 million for the quarter, compared to analyst estimates of $85.38 million. Fulgent Genetics had a negative return on equity of 2.22% and a negative net margin of 18.75%.Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. As a group, sell-side analysts predict that Fulgent Genetics will post -2.48 EPS for the current fiscal year.

Institutional Trading of Fulgent Genetics

Several institutional investors have recently added to or reduced their stakes in FLGT. Amundi boosted its stake in Fulgent Genetics by 289.2% in the 1st quarter. Amundi now owns 34,316 shares of the company’s stock valued at $583,000 after purchasing an additional 25,500 shares during the period. Goldman Sachs Group Inc. boosted its stake in Fulgent Genetics by 28.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 202,820 shares of the company’s stock valued at $3,428,000 after purchasing an additional 45,279 shares during the period. Legal & General Group Plc boosted its stake in Fulgent Genetics by 14.1% in the 2nd quarter. Legal & General Group Plc now owns 21,025 shares of the company’s stock valued at $418,000 after purchasing an additional 2,599 shares during the period. Rhumbline Advisers boosted its stake in Fulgent Genetics by 2.4% in the 2nd quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock valued at $659,000 after purchasing an additional 785 shares during the period. Finally, American Century Companies Inc. boosted its stake in Fulgent Genetics by 8.0% in the 2nd quarter. American Century Companies Inc. now owns 52,168 shares of the company’s stock valued at $1,037,000 after purchasing an additional 3,860 shares during the period. 48.06% of the stock is currently owned by institutional investors.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.